Clinical Trial Update: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for GSK's RSV vaccine based on chimpanzee adenovector (ChAd155-RSV) in RSV-seropositive infants; Phase 1/Phase 2 completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• ChAd155-RSV (GSK3389245A) (GSK3389245A)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-10-28